Specialty Pharmaceutical Company dedicated to patients living with chronic conditions

Filing date Description Form Filing Group Filer View

Initial filing by director officer or owner of more than ten percent.

3
3,4,5
Vollins James 0000899243-18-028229.pdf 0000899243-18-028229.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Vollins James 0000899243-18-028231.pdf 0000899243-18-028231.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0000899243-18-028048.pdf 0000899243-18-028048.rtf View HTML

Report of unscheduled material events or corporate event

8-K
Current Reports
0001193125-18-310718.pdf 0001193125-18-310718.rtf 0001193125-18-310718.xls View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Plesha Scott M. 0000899243-18-027471.pdf 0000899243-18-027471.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0000899243-18-026093.pdf 0000899243-18-026093.rtf View HTML

Report of unscheduled material events or corporate event

8-K
Current Reports
0001193125-18-274256.pdf 0001193125-18-274256.rtf 0001193125-18-274256.xls View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0000899243-18-024561.pdf 0000899243-18-024561.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Davis Todd C 0000899243-18-023257.pdf 0000899243-18-023257.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0000899243-18-022886.pdf 0000899243-18-022886.rtf View HTML

Copyright Morningstar

BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Thank you. We will get back to you soon